BPC-157 · research summary

Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.

Pharmaceuticals (Basel, Switzerland) · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Systematic review of preclinical and clinical evidence regarding PRP, growth factors, and BPC 157 in musculoskeletal injuries
“As a novel theoretical and practical advantage, preclinical to clinical evidence, this systematic review of PRP, growth factors, and stable gastric pentadecapeptide BPC 157 efficacy in complex musculoskeletal and junctional injuries emphasizes the cytoprotection concept, healing to restore tissue integrity.”

Reported findings

Growth factors improve tendon, ligament, and muscle healing when delivered locally with carriers, but show limited or no efficacy in junctional healing and may fail in muscle lesions.
“growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs) delivered locally with various carriers improve tendon, ligament, and muscle healing; however, some (PDGF, TGF-β1, IGF-1) may fail in muscle lesions, and all show limited or no efficacy in junctional healing.”
BPC 157 acts alone without a carrier to provide beneficial effects on tendon, ligament, muscle, and junctional healing.
“Moreover, without any carrier, BPC 157 acts alone, combining beneficial effects on tendon, ligament, and muscle injuries with osteotendinous, myotendinous, and muscle-to-bone healing.”
BPC 157 demonstrated consistent efficacy in rat studies across various administration routes, suggesting translational potential.
“In rat studies, across systemic (intraperitoneal, intragastric, or drinking water) and local (cream) administration, BPC 157 consistently demonstrated efficacy, indicating considerable translational potential.”

Source: PubMed 41754849 · DOI 10.3390/ph19020309 · all study summaries

Study type

Systematic review of preclinical and clinical evidence regarding PRP, growth factors, and BPC 157 in musculoskeletal injuries

“As a novel theoretical and practical advantage, preclinical to clinical evidence, this systematic review of PRP, growth factors, and stable gastric pentadecapeptide BPC 157 efficacy in complex musculoskeletal and junctional injuries emphasizes the cytoprotection concept, healing to restore tissue integrity.”

Reported findings

Growth factors improve tendon, ligament, and muscle healing when delivered locally with carriers, but show limited or no efficacy in junctional healing and may fail in muscle lesions.

“growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs) delivered locally with various carriers improve tendon, ligament, and muscle healing; however, some (PDGF, TGF-β1, IGF-1) may fail in muscle lesions, and all show limited or no efficacy in junctional healing.”

BPC 157 acts alone without a carrier to provide beneficial effects on tendon, ligament, muscle, and junctional healing.

“Moreover, without any carrier, BPC 157 acts alone, combining beneficial effects on tendon, ligament, and muscle injuries with osteotendinous, myotendinous, and muscle-to-bone healing.”

BPC 157 demonstrated consistent efficacy in rat studies across various administration routes, suggesting translational potential.

“In rat studies, across systemic (intraperitoneal, intragastric, or drinking water) and local (cream) administration, BPC 157 consistently demonstrated efficacy, indicating considerable translational potential.”